期刊文献+

新肠道病毒71型病毒样颗粒的制备 被引量:2

Preparation of the EV71 VLPs
下载PDF
导出
摘要 目的:研究新肠道病毒71型(Enterovirus 71,EV71)病毒样颗粒(Virus-like particles,VLPs)的制备方法。方法:依据昆虫细胞偏爱密码子优化EV71 P1和EV71 3CD基因,将二者分别克隆至供体质粒pFastBac Dual多角体蛋白启动子pPh和pP10上;构建重组pFastBac Dual EV71 P1-3CD质粒,并与Bacmid质粒转座后,获得重组杆状病毒表达质粒转染至Sf9细胞,应用PCR、免疫荧光、SDS-Page和Western blot方法鉴定EV71 VLPs表达情况,最后利用蔗糖密度梯度离心的方法纯化EV71 VLPs。结果:经昆虫密码子优化的EV71 P1和EV71 3CD基因,利用Bac-to-Bac系统成功组装了EV71 VLPs,纯化EV71VLPs的浓度为0.817 mg/ml,纯度>90%。结论:成功地构建了重组杆状病毒EV71 P1-3CD Bacmid表达质粒,并表达和纯化了EV71 VLPs,这为今后EV71 VLPs疫苗的研究奠定了基础。 Objective:The aim of the present study was to prepared EV71 VLPs,which was important for further studies in term of EV71 VLPs.Methods:Based on preferred codon optimization of insect cells,EV71 P1 and EV71 3CD genes were cloned into the donor vector pFastBac Dual under the polyhedrin promoter pPh and pP10,and the constructed donor plasmid pFastBac Dual-P1-3CD was transformed to E.coli DH10Bac.The obtained recombinant baculovirus plasmid Bacmid-P1-3CD was transfected into Sf9 cells to prepare recombinant baeulovirus and the expressed products were identified by PCR,IFA,SDS-Page and Western-Blot.Then the VLPs were purified by sucrose density gradient centrifugation.Results:The EV71 P1 and EV71 3CD genes insects codon optimized were assembled EV71 VLPs successfully by Bac-to-Bac system.Concentration of purified EV71 VLPs was 0.817 mg/ml,purity of 90%.Conclusion:Finally,the pFastBac Dual EV71 P1-3CD was constructed,and EV71 VLPs were expressed and purified successfully,which provide a valuable platform for the future EV71 VLPs vaccine research.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2012年第11期1014-1018,1031,共6页 Chinese Journal of Immunology
关键词 EV71 Bac-to-Bac表达系统 病毒样颗粒 EV71 Bac-to-Bac Baculovirus Expression System Virus-like particles
  • 相关文献

参考文献2

二级参考文献23

  • 1Chung YC, Ho MS, Wu JC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune re sponses and protects mice against lethal challenge[J]. Vaccine,2008,26(15) :1855- 1862.
  • 2Wu CN, Lin YC, Fann C, et al. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus[J]. Vaccine,2001,20(5 6) :895-904.
  • 3Chiu CH, Chu C, He CC, et al. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71[J]. Microbes Infect, 2006,8(7) :1671- 1678.
  • 4Kim JY, Jeon ES, Lim BK, et al. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge[J]. Vac cine,2005,23(14) : 1672 -1679.
  • 5Henke A, Chiang CS, Zell R, et al. Co expression of inter leukin 2 to increase the efficacy of DNA vaccine-mediated protection in coxsackievirus B3-infected mice[J]. Antiviral Res,2004,64(2) :131-136.
  • 6Henke A, Jarasch N, Martin U, et al. Characterization of the protective capability of a recombinant coxsackievirus B3 variant expressing interferon-gamma [J].Viral Immunol, 2008,21(1) :38-48.
  • 7Ooi EE, Phoon MC, Ishak B, et al. Seroepidemiology of human enterovirus 71, Singapore [J]. Emerg Infect Dis, 2002, 8(9):995- 997.
  • 8Lukashev, AN. Role of recombination in evolution of enteroviruses[J]. Rev Med Virol,2005, 15(3) : 157-167.
  • 9Oberste MS, Maher K, Pallansch MA. Evidence for frequent recombination within species human enterovirus B based on complete genomic sequences of all thirty-seven serotypes[J].J Virol,2004,78(2) :855-867.
  • 10Chan YF, Abubakar S. Recombinant human enterovirus 71 in hand, foot and mouth disease patients[J].Emerg Infect Dis, 2004, 10(8) :1468-1470.

共引文献66

同被引文献28

  • 1严维巍,崔治中,王永坤.在昆虫细胞中表达能自聚成病毒样颗粒的兔出血症病毒衣壳蛋白[J].病毒学报,2004,20(4):333-337. 被引量:7
  • 2彭建明,李金明.病毒样颗粒在免疫测定中的应用研究进展[J].中华检验医学杂志,2005,28(2):214-216. 被引量:27
  • 3Brady JN, Consigli RA. Chromatographic separation of the polyoma virus proteins and renaturation of the isolated VP1 major capsid protein[ J]. J Virol, 1978, 27:436-442.
  • 4McAleer WJ, buynak EB, Maigetter RZ, et al. Human Hepatitis B Vaccine from recombinant yeast[ J]. Nature, 1984, 307:178-180.
  • 5Sootti N,Rybicki EP. Virus-like particles produced in plants as potential Vaccines[ J]. Expert Rev Vaccines, 2013, 12:211-224.
  • 6Liu F, Ge S, Li I, et al. Virus-like particles:potential veterinary vaccine immunogens [J]. Res Vet Sci, 2011,93:553-559.
  • 7Andris Z. Construction and characterization of virus-like partides:a review[ J]. Mol Biotechnol, 2013, 53:92-107.
  • 8Petry H,Coldmann C, Ast O, et al. The use of virus-like particles for gene transfer [ J]. Curr Opin Mol Ther, 2003, 5:524-528.
  • 9Mihailova M, Boos M, Petrovskis I, et al. Recombinant virus-like particles as a carrier of B-and T-cell epitopes of hepatitis C virus(HCV) [ J ]. Vaccine, 2006, 24:43694377.
  • 10Shang W, Liu J, Yang J, et al. Dengue virus-like particles:construction and application[ J]. Appl Microbiol Biotechnol, 2012, 94:39-46.

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部